A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

Completed · Phase 3 · Has a placebo group

Conditions studied: Psoriasis

In brief

The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.

Key facts

Study ID

NCT01276639

Run by

Pfizer

People needed

901

Starts

2011-03-01

Expected to finish

2013-04-01

Last updated by the study team

2014-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering as least 10%of body surface area
• a Psoriasis Area and Severity Index (PASI) score of 12 and are considered to be candidates for systemic or light therapy
• No evidence of active or latent tuberculosis

You may not qualify if…

• Non-plaque or drug induced forms of psoriasis
• cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB)
• any uncontrolled significant medical condition

Where it is running

• University of California, Irvine - Dermatology Research — Irvine, California, United States
• Skin Surgery Medical Group, Inc. — San Diego, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Cherry Creek Research, Inc. — Denver, Colorado, United States
• The Savin Center, P.C. — New Haven, Connecticut, United States
• Renstar Medical Research — Ocala, Florida, United States
• Academic Alliance in Dermatology — Tampa, Florida, United States
• Atlanta Dermatology, Vein & Research Center, P.C. — Alpharetta, Georgia, United States
• Peachtree Dermatology Associates Research Center — Atlanta, Georgia, United States
• MedaPhase Inc. — Newnan, Georgia, United States
• Southern Illinois University School of Medicine — Springfield, Illinois, United States
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• Massachusetts General Hospital - Clinical Unit for Research Trials and Outcomes in Skin — Boston, Massachusetts, United States
• Skin Specialists, P.C. — Omaha, Nebraska, United States
• New York University School of Medicine — New York, New York, United States
• Skin Search of Rochester, Inc. — Rochester, New York, United States
• Raleigh Radiology Blue Ridge — Raleigh, North Carolina, United States
• Wake Research Associates — Raleigh, North Carolina, United States
• Central Sooner Research — Norman, Oklahoma, United States
• Baker Allergy, Asthma and Dermatology Research Center, LLC — Lake Oswego, Oregon, United States
• University of Pittsburgh Medical Center - Department of Dermatology — Pittsburgh, Pennsylvania, United States
• Clinical Partners, LLC — Johnston, Rhode Island, United States
• Dermatology Associates of Knoxville, PC — Knoxville, Tennessee, United States
• Radiant Research, Inc. — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.